Top strategic considerations when entering the biosimilars market

In Clinical Trials, Regulation and Compliance by charlottebLeave a Comment

biosimilars, immunogenicity, clinical, regulatory

Biosimilars market: Would it help you to know the high risk areas when entering the biosimilars market? Do you want to know key strategic considerations the industry are looking at before they make the move into biosimilars?

Our recent 2012 Survey for the World Biosimilars Congress asked the top players in the biosimilars arena what is currently driving their continued interest.

They responded with these top 4 answers below:

  • Regulatory environment
  • Intellectual property
  • Clinical development
  • Immunogenicity

Do these match with your company's priorities or would you like to put another driver into the mix? Let us know by commenting below!

Interested in reading more on this topic?  Take a look here: Top drivers fuelling industries biosimilar engagement today

For more updates on pharma, biotech and R&D, follow us on Twitter: @biopharmaevents or join our LinkedIn group: BioPharma- Networking for Pharmaceuticals, Biotech and R&D

Leave a Comment

Current ye@r *